NOTA TÉCNICA DE RESPOSTA RÁPIDA (NTRR) - Nº 002/2023 AFLIBERCEPTE

Abstract

Title/question: What is the budgetary impact of Aflibercept compared to Ranibizumab, for the treatment of patients with Diabetic Macular Edema involving the center of the fovea, within the framework of the University Hospital Maria Aparecida Pedrossian, Humap-UFMS/Ebserh. Target Population: Patients affected by Diabetic Macular Edema involving the center of the fovea. Technology: Aflibercept (Eylia®) Comparator: Ranibizumab (Lucentis®) Search for practiced prices: the cost of each bottle of Aflibercept in this NTRR was estimated at BRL 3,852.36, according to the average calculated and Ranibizumab was BRL 2,751.78. Budget Impact: As provided in the merger order, 30 vials of Aflibercept per month would be required. Therefore, the estimated annual cost would be R$ 1,386,849.60. Despite having a SUS code related to the procedure, there would be an annual deficit of R$ 1,161,028.80. Conclusion: The PCDT of Diabetic Retinopathy shows that both Aflibercept and Ranibizumab are safe and effective therapeutic options to treat it. Evidence points out that Ranibizumab has a smaller budgetary impact, but that both are not fully reimbursed by the SUS table. Recommendations: It is recommended that the applicant evaluate Ranibizumab as a therapeutic option for the treatment of diabetic retinopathy, and it is up to the administrative manager to analyze, in the light of the data presented here, whether the incorporation of either or both is financially viable.